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Clinical PerspectiveWhat Is New?Reported cases of isolated mitral valve prolapse and sudden cardiac death indicate that young females with bileaflet redundant leaflets are predominantly affected.Clinical predictors of sudden cardiac death in isolated mitral valve prolapse are lacking.The estimated incidence of sudden cardiac death in mitral valve prolapse is 217 events per 100 000 person‐years from previous studies.What Are the Clinical Implications?Further work is needed to understand the complex relationship between mitral valve prolapse and sudden cardiac death.Standardized reporting of clinical, electrophysiological, echocardiographic, and other cardiac imaging variables with documentation of long‐term outcomes is required.

 {#jah33692-sec-0008}

Mitral valve prolapse (MVP) is characterized by the atrial displacement of the mitral valve (MV) leaflet(s) during ventricular systole. The estimated prevalence of MVP is 2.4%, with approximately equal sex distribution.[1](#jah33692-bib-0001){ref-type="ref"}

Although most MVP cases are thought to be benign, reported complications include mitral regurgitation (MR) requiring MV surgery, infective endocarditis, stroke, and sudden cardiac death (SCD).[2](#jah33692-bib-0002){ref-type="ref"} The association between MVP and SCD (a potential high‐risk MVP subtype) has been reported but the underlying mechanisms remain poorly understood. It is postulated that SCD in individuals with MVP is caused by ventricular arrhythmias (VAs),[3](#jah33692-bib-0003){ref-type="ref"}, [4](#jah33692-bib-0004){ref-type="ref"} although this association remains controversial.[1](#jah33692-bib-0001){ref-type="ref"}, [2](#jah33692-bib-0002){ref-type="ref"}, [5](#jah33692-bib-0005){ref-type="ref"} The initial description of MVP involved cardiac auscultation, cineangiography, and histopathological examination.[6](#jah33692-bib-0006){ref-type="ref"} This led to an abundance of literature describing MVP at autopsy,[7](#jah33692-bib-0007){ref-type="ref"}, [8](#jah33692-bib-0008){ref-type="ref"}, [9](#jah33692-bib-0009){ref-type="ref"}, [10](#jah33692-bib-0010){ref-type="ref"}, [11](#jah33692-bib-0011){ref-type="ref"} provoking discussions about a causal relationship between MVP and SCD.

The application of M‐mode and 2‐dimensional echocardiography for the diagnosis of MVP posed challenges as the identification of MVP shifted from the long axis view,[12](#jah33692-bib-0012){ref-type="ref"}, [13](#jah33692-bib-0013){ref-type="ref"} to either a long axis or apical 4‐chamber view,[14](#jah33692-bib-0014){ref-type="ref"} and then back to the long axis view as the gold standard for diagnosing MVP.[15](#jah33692-bib-0015){ref-type="ref"} These changes resulted in a significant rise and fall in the prevalence of MVP,[1](#jah33692-bib-0001){ref-type="ref"}, [16](#jah33692-bib-0016){ref-type="ref"} with implications for the estimated incidence of SCD.

We aimed to comprehensively evaluate all reported cases of MVP and SCD in the current literature to better characterize the potential high‐risk MVP subtype and to determine whether clinical and diagnostic parameters can predict which patients with MVP were at a higher risk of experiencing SCD. Furthermore, based on published studies, we provide an estimated incidence of SCD in MVP.

Methods {#jah33692-sec-0009}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure as source data for this systematic review are available from web‐based medical libraries.

Case Identification and Search Strategy {#jah33692-sec-0010}
---------------------------------------

We conducted a literature search for cases of MVP with SCD or cardiac arrest in PubMed and Embase on January 1, 2018, using Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines.[17](#jah33692-bib-0017){ref-type="ref"} PubMed search terms were "mitral valve prolapse" AND "cardiac arrest" OR "mitral valve prolapse" AND "sudden cardiac death" OR "mitral valve prolapse" AND "sudden death" OR "mitral valve prolapse" AND "arrhythmia." Embase search terms were "mitral valve prolapse" AND "heart ventricular fibrillation" OR "mitral valve prolapse" AND "heart arrest" OR "mitral valve prolapse" AND "sudden death" OR "mitral valve prolapse" AND "sudden cardiac death" OR "mitral valve prolapse" AND "heart ventricular tachycardia" OR "mitral valve prolapse" AND "heart arrhythmia" OR "mitral valve prolapse" AND "heart ventricular arrhythmia."

Titles and abstracts were screened for relevance by 2 reviewers (H.H. and F.J.H.) and bibliographies of all included publications were screened to identify additional references. Screening of the above search result was also conducted to identify articles, which investigated whether patients with MVP had certain clinical, electrophysiological, or imaging predictors that were associated with VAs or SCD. Finally, prospective studies of patients with MVP, which reported SCD outcomes, were included to estimate the incidence of SCD in MVP. Details of the search algorithm are shown in Figure [1](#jah33692-fig-0001){ref-type="fig"}.

![Search algorithm. MVP indicates mitral valve prolapse; SCD, sudden cardiac death.](JAH3-7-e010584-g001){#jah33692-fig-0001}

Included articles were any cases of MVP with SCD or MVP with cardiac arrest and documented rhythm reported in English. Cases of MVP and SCD were separated into isolated MVP (iMVP) and nonisolated MVP (non‐iMVP) depending on whether there was another potential cause of death or cardiac arrest. Reports from case series were included if individual patient age and sex could be determined. Cases were excluded if they described VAs that did not result in cardiac arrest or survived cardiac arrest without a documented rhythm. Reports were also excluded if they were published only in abstract form.

Regarding predictors of SCD or VAs, we excluded articles that used healthy patients (as opposed to those with high‐ versus low‐risk MVP) as controls. We also excluded articles with nonsignificant findings or outcomes that were not related to VAs or SCD.

Regarding the incidence of SCD in MVP, we used prospective studies that included a mean patient age older than 18 years, at least 100 patients, and minimum follow‐up duration of 24 months.

Statistical Analysis {#jah33692-sec-0011}
--------------------

Continuous data are presented as either medians with interquartile ranges (IQRs) or means with SDs as indicated. Categorical data are presented as absolute numbers and percentages.

Results {#jah33692-sec-0012}
=======

In total, 161 cases of MVP with either SCD or cardiac arrest were identified from 79 studies, with 123 cases of iMVP and 38 cases of non‐iMVP. A further 22 studies investigated predictors of VAs or SCD. Comprehensive details of all included studies are presented in Tables [S1](#jah33692-sup-0001){ref-type="supplementary-material"} and [S2](#jah33692-sup-0001){ref-type="supplementary-material"}. There were 3 studies that provided long‐term follow‐up data regarding SCD in MVP.[18](#jah33692-bib-0018){ref-type="ref"}, [19](#jah33692-bib-0019){ref-type="ref"}, [20](#jah33692-bib-0020){ref-type="ref"}

Clinical Characteristics in iMVP and SCD {#jah33692-sec-0013}
----------------------------------------

Clinical characteristics of the cases are summarized in Table [1](#jah33692-tbl-0001){ref-type="table"}. The age‐sex distribution of the index event of cardiac arrest or death is illustrated in Figure [2](#jah33692-fig-0002){ref-type="fig"}.

###### 

Baseline Characteristics in Cases of MVP and SCD or Cardiac Arrest

  Baseline Characteristics                                        All Cases (N=161)   iMVP (n=123)   Non‐iMVP (n=38)
  --------------------------------------------------------------- ------------------- -------------- -----------------
  Age, y                                                                                             
  Range                                                           6--79               6--79          8--76
  Mean±SD                                                         37±16               36±16          40±17
  Median (IQR)                                                    32 (25--51)         30 (25--47)    36 (26--56)
  Female sex                                                      109 (68)            85 (69)        24 (63)
  SCD                                                             100 (62)            75 (61)        25 (66)
  Circumstances of death or cardiac arrest                        n=98                n=74           n=24
  Sleeping                                                        6 (6)               5 (7)          1 (4)
  Normal daily activity[a](#jah33692-note-0002){ref-type="fn"}    45 (46)             34 (46)        11 (46)
  Exertion or soon after[b](#jah33692-note-0003){ref-type="fn"}   22 (22)             17 (23)        5 (21)
  Emotional stress                                                6 (6)               4 (5)          2 (8)
  Driving                                                         4 (4)               4 (5)          0
  Anesthesia related[c](#jah33692-note-0004){ref-type="fn"}       6 (6)               5 (7)          1 (4)
  Pregnancy related[d](#jah33692-note-0005){ref-type="fn"}        4 (4)               3 (4)          1 (4)
  Witnessed in hospital                                           5 (5)               2 (3)          3 (13)
  Prior symptoms[e](#jah33692-note-0006){ref-type="fn"}           n=71                n=48           n=23
  Dizziness                                                       14 (20)             11 (23)        3 (13)
  Syncope                                                         25 (35)             14 (29)        11 (48)
  Dyspnea                                                         9 (13)              5 (10)         4 (17)
  Chest pain                                                      20 (28)             15 (31)        5 (22)
  Palpitations                                                    39 (55)             28 (58)        11 (48)
  Fatigue                                                         6 (8)               4 (8)          2 (9)
  None                                                            12 (17)             10 (21)        2 (9)
  Previous cardiac arrest                                         n=20                n=14           n=6
  Yes[f](#jah33692-note-0007){ref-type="fn"}                      8 (40)              3 (21)         5 (83)
  No                                                              12 (60)             11 (79)        1 (21)
  Medication use                                                  n=57                n=32           n=25
  Digoxin                                                         7 (13)              1 (3)          6 (24)
  β‐Blocker[g](#jah33692-note-0008){ref-type="fn"}                16 (28)             7 (22)         9 (36)
  Class 1[h](#jah33692-note-0009){ref-type="fn"}                  10 (18)             0              10 (40)
  Amiodarone                                                      1 (2)               0              1 (4)
  Other medications[i](#jah33692-note-0010){ref-type="fn"}        15 (26)             9 (28)         6 (24)
  Nil                                                             17 (30)             16 (50)        1 (4)
  Family history of SCD                                           n=28                n=22           n=6
  Yes                                                             4 (14)              3 (14)         1 (17)
  No                                                              24 (86)             19 (86)        5 (83)

Values are expressed as number (percentage) unless otherwise indicated. iMVP indicates isolated mitral valve prolapse; MVP, mitral valve prolapse; IQR, interquartile range; SCD, sudden cardiac death.

Includes death at home, work (nonphysical), or during commute.

One case was after sexual intercourse.

Four cases during induction, 1 case during anesthesia reversal, and 1 case during peripheral arterial puncture.

Two cases were during pregnancy, 1 case during epidural injection, 1 case (classified as nonisolated mitral valve prolapse \[non‐iMVP\]) was 2 days postpartum with likely tachycardia‐mediated cardiomyopathy caused by permanent junctional reciprocating tachycardia.

Multiple symptoms in some cases.

Three cases with documented ventricular fibrillation.

Two patients taking sotalol (classified as non‐iMVP).

Includes propafenone, procainamide, mexilitine, quinidine, disopyramide, and flecainide.

Includes amoxicillin, diuretics, antiepileptics, primidone, methyldopa, perindopril, trastuzumab, inhaled glucocorticosteroids, danazol, domperidone, and various psychotropic agents in 3 cases.

John Wiley & Sons, Ltd

![Age at time of death or cardiac arrest in mitral valve prolapse according to sex.](JAH3-7-e010584-g002){#jah33692-fig-0002}

For patients with iMVP, the median age was 30 years (range 6 to 79 years), female sex accounted for 69% of cases, and 61% were SCD cases. The median age for female cases was 28 (IQR, 24--41) years and the median age for male cases was 39 (IQR, 28--53) years. Two cases occurred in individuals younger than 10 (ages 6 and 7), and a further 6 cases in individuals between 10 and 18 years. Activity at the time of cardiac arrest included routine daily activities (46%), exertion related (23%), emotional stress (5%), sleeping (7%), driving (5%), and pregnancy related (4%). Seven cases had cardiac arrest while in the hospital, with 5 occurring in the setting of general anesthesia.

Preceding symptoms included palpitations (58%), syncope (29%), chest pain (31%), dizziness (23%), and fatigue (8%). Only 21% of patients were reported to be asymptomatic before the index event. Three cases had a history of cardiac arrest, although none of these cases overlapped with those who had prior syncope.

Prior medication use was reported in 32 cases, of which 8 (25%) involved patients taking either a β‐blocker or digoxin at the time of cardiac arrest or SCD and 50% who were not taking any medications. One patient was taking multiple psychotropic medications,[21](#jah33692-bib-0021){ref-type="ref"} while another case described MVP and SCD in a patient with markedly elevated concentrations of caffeine (from an energy supplement).[22](#jah33692-bib-0022){ref-type="ref"}

A positive family history for SCD was reported in 14% of cases. One case described a possible familial cluster of malignant MVP involving a 14‐year‐old female with SCD and iMVP, 3 first‐degree relatives with SCD (mother aged 36, sister aged 11, and brother aged 12 years who had thickening of his MV) and 3 of 7 remaining siblings with MVP.[8](#jah33692-bib-0008){ref-type="ref"}

Electrophysiological Findings in iMVP and SCD {#jah33692-sec-0014}
---------------------------------------------

Electrophysiological findings for cases of MVP and SCD or cardiac arrest are shown in Table [2](#jah33692-tbl-0002){ref-type="table"}.

###### 

Electrical Findings in Cases of MVP and SCD or Cardiac Arrest

  Electrical Findings                                           All Cases   iMVP      Non‐iMVP
  ------------------------------------------------------------- ----------- --------- ----------
  Baseline ECG changes[a](#jah33692-note-0012){ref-type="fn"}   n=81        n=59      n=22
  Inferior TWI[b](#jah33692-note-0013){ref-type="fn"}           15 (19)     14 (24)   1 (5)
  Other ST‐T changes[c](#jah33692-note-0014){ref-type="fn"}     16 (20)     11 (19)   5 (23)
  PVCs[d](#jah33692-note-0015){ref-type="fn"}                   40 (49)     30 (51)   10 (45)
  Normal                                                        23 (28)     19 (32)   4 (18)
  Atrial fibrillation                                           9 (11)      5 (8)     4 (18)
  Left ventricular hypertrophy                                  5 (6)       2 (3)     3 (14)
  Other[e](#jah33692-note-0016){ref-type="fn"}                  9 (11)      5 (8)     4 (18)
  Holter findings                                               n=36        n=24      n=12
  No PVCs                                                       4 (11)      2 (8)     2 (17)
  PVCs and couplets only                                        20 (56)     15 (63)   5 (42)
  Nonsustained VT                                               10 (28)     7 (29)    3 (25)
  TDP/VF                                                        2 (6)       0         2 (17)
  Cardiac arrest rhythm                                         n=72        n=53      n=19
  VF                                                            58 (81)     43 (81)   15 (79)
  VT                                                            9 (13)      6 (11)    3 (16)
  TDP                                                           3 (4)       2 (4)     1 (5)
  Asystole                                                      2 (3)       2 (4)     0
  PVS findings                                                  n=26        n=22      n=4
  Normal                                                        13 (50)     12 (55)   1 (25)
  Nonsustained VT                                               6 (23)      5 (23)    1 (25)
  Sustained VT                                                  2 (8)       1 (5)     1 (25)
  VF                                                            5 (19)      4 (18)    1 (25)
  Site of origin of PVCs or VT                                  n=10        n=6       n=4
  Left ventricle                                                3 (30)      2 (33)    1 (25)
  Right ventricle                                               5 (50)      4 (67)    1 (25)
  Both                                                          2 (20)      0         2 (50)

Values are expressed as number (percentage). MVP indicates mitral valve prolapse; PVS, programmed ventricular stimulation; SCD, sudden cardiac death; TDP, torsades de pointes; VF, ventricular fibrillation; VT, ventricular tachycardia.

Multiple changes in some cases.

All leads (11 cases), lead III (1 case), leads II and III (2 cases), and leads III and aVF (1 case).

T‐wave inversion (TWI) in lateral leads (7 cases), TWI in V1--V3 (1 case), diffuse changes (1 case), and not specified (7 cases).

Includes multiple premature ventricular complexes (PVCs) (1), multifocal PVCs (6), bigeminy (3), and couplets (1).

Includes premature atrial complexes, bundle branch blocks, and accessory pathway (isolated mitral valve prolapse \[iMVP\] cases); Brugada pattern, prolonged QT, left axis deviation, and poor R‐wave progression (nonisolated mitral valve prolapse \[non‐iMVP\] cases).

John Wiley & Sons, Ltd

On baseline ECG, premature ventricular complexes (PVCs) were frequently reported (51%), while T‐wave inversion in the inferior leads (24%) and other T‐wave changes (19%) were also common. Seven cases described combined inferior and lateral T‐wave changes. Normal baseline ECG findings were described in 32% of cases.

Among patients who underwent Holter monitoring, PVCs and couplets were the most common finding (63%), followed by nonsustained VT (29%). No abnormalities were recorded in 8%.

The site of origin of VT or PVCs was available (either reported or interpreted based on published ECG) in 6 cases. Both left and right bundle branch morphologies (in V1) were present with regard to VT or PVC origin. Four cases (all VT) published 12‐lead ECGs allowing for interpretation of possible VT origin (Figure [3](#jah33692-fig-0003){ref-type="fig"}).[23](#jah33692-bib-0023){ref-type="ref"}, [24](#jah33692-bib-0024){ref-type="ref"}, [25](#jah33692-bib-0025){ref-type="ref"}, [26](#jah33692-bib-0026){ref-type="ref"} Cardiac arrest rhythm was reported in 53 cases and was caused by ventricular fibrillation (VF) (81%), VT (11%), torsades de pointes (4%), and asystole (4%). Six cases documented the initiation of malignant VAs with 5 cases showing PVC‐triggered polymorphic VT or VF (Figure [4](#jah33692-fig-0004){ref-type="fig"}).[24](#jah33692-bib-0024){ref-type="ref"}, [27](#jah33692-bib-0027){ref-type="ref"}, [28](#jah33692-bib-0028){ref-type="ref"}, [29](#jah33692-bib-0029){ref-type="ref"}, [30](#jah33692-bib-0030){ref-type="ref"}, [31](#jah33692-bib-0031){ref-type="ref"} In total, there were 10 cases of autopsy‐confirmed MVP (6 with iMVP and 4 with non‐iMVP) with documented cardiac rhythm at the time of death, and they all had VF.[10](#jah33692-bib-0010){ref-type="ref"}, [22](#jah33692-bib-0022){ref-type="ref"}, [29](#jah33692-bib-0029){ref-type="ref"}, [32](#jah33692-bib-0032){ref-type="ref"}, [33](#jah33692-bib-0033){ref-type="ref"}, [34](#jah33692-bib-0034){ref-type="ref"}, [35](#jah33692-bib-0035){ref-type="ref"}, [36](#jah33692-bib-0036){ref-type="ref"}, [37](#jah33692-bib-0037){ref-type="ref"}, [38](#jah33692-bib-0038){ref-type="ref"}

![Twelve‐lead ECGs of ventricular tachycardia. Left and right bundle morphology interpretation based on V1 appearance. **A**, Left bundle morphology, inferior axis (isolated mitral valve prolapse \[iMVP\], reproduced with permission from Elsevier).[23](#jah33692-bib-0023){ref-type="ref"} **B**, Left bundle morphology, inferior axis (nonisolated iMVP \[non‐iMVP\], patient taking procainamide, reproduced with permission from Elsevier).[24](#jah33692-bib-0024){ref-type="ref"} **C**, Left bundle morphology, superior axis (iMVP, reproduced with permission from BMJ Publishing Group Ltd.).[25](#jah33692-bib-0025){ref-type="ref"} **D**, Right bundle morphology, superior axis (iMVP, reproduced with permission from Elsevier).[26](#jah33692-bib-0026){ref-type="ref"}](JAH3-7-e010584-g003){#jah33692-fig-0003}

![Documented onset of ventricular arrhythmias. **A**, Late diastolic premature ventricular complex (PVC)--triggered polymorphic ventricular tachycardia (VT; nonisolated mitral valve prolapse \[non‐iMVP\], patient taking quinidine, reproduced with permission from Elsevier)[27](#jah33692-bib-0027){ref-type="ref"} **B**, Possible PVC‐triggered polymorphic VT (isolated mitral valve prolapse \[iMVP\], reproduced with permission from Elsevier)[28](#jah33692-bib-0028){ref-type="ref"} **C**, Monomorphic VT with pace termination (non‐iMVP, patient taking procainamide, reproduced with permission from Elsevier)[24](#jah33692-bib-0024){ref-type="ref"} **D**, Late diastolic couplets triggering polymorphic then fast VT (non‐iMVP, patient had arrhythmogenic right ventricular cardiomyopathy, reproduced with permission from Elsevier)[29](#jah33692-bib-0029){ref-type="ref"} **E**, Late diastolic PVC--triggered polymorphic VT with varying PVC morphologies in rhythm strip (iMVP, reproduced with permission from Elsevier)[30](#jah33692-bib-0030){ref-type="ref"} **F**, (bottom 2 strips), PVC--triggered recurrent VF (iMVP, reproduced with permission from Elsevier).[31](#jah33692-bib-0031){ref-type="ref"}](JAH3-7-e010584-g004){#jah33692-fig-0004}

Programmed ventricular stimulation was reported for 22 cases using various induction protocols. The findings included sustained VT (5%), nonsustained VT (23%), VF (18%), and no induction of VAs (55%).

Cardiac Imaging Findings in iMVP and SCD {#jah33692-sec-0015}
----------------------------------------

Cardiac imaging findings for cases of MVP and SCD or cardiac arrest are shown in Table [3](#jah33692-tbl-0003){ref-type="table"}.

###### 

Imaging Findings in Cases of MVP and SCD or Cardiac Arrest

  Imaging Findings                                             All Cases   iMVP      Non‐iMVP
  ------------------------------------------------------------ ----------- --------- ----------
  Leaflet involvement[a](#jah33692-note-0018){ref-type="fn"}   n=83        n=57      n=26
  Bileaflet                                                    57 (69)     40 (70)   17 (65)
  Posterior leaflet                                            23 (28)     15 (26)   8 (30)
  Anterior leaflet                                             3 (4)       2 (4)     1 (4)
  MR severity                                                  n=38        n=23      n=15
  Nil/trivial                                                  9 (24)      6 (26)    3 (20)
  Mild                                                         12 (32)     9 (39)    3 (20)
  Moderate                                                     8 (21)      4 (17)    4 (27)
  Severe                                                       9 (24)      4 (17)    5 (33)

Values are expressed as number (percentage). iMVP indicates isolated mitral valve prolapse; non‐MVP, nonisolated mitral valve prolapse; MVP, mitral valve prolapse; MR, mitral regurgitation; SCD, sudden cardiac death.

Determination based on either noninvasive imaging reports and/or autopsy reports.

John Wiley & Sons, Ltd

Leaflet involvement was most commonly bileaflet (70%), then posterior leaflet (26%) and anterior leaflet (4%). Severe MR was present in 17% of cases. Six cases reported MV surgery (3 repair and 3 replacement), with 3 cases describing improvement in VAs (follow‐up duration ranged from 2 to 3 years), 2 cases describing recurrent VT requiring treatment even after surgery, and 1 case with unreported arrhythmia outcomes.

Two cases reported cardiac magnetic resonance imaging findings, with 1 case reporting anteroseptal and posterior left ventricular wall fibrosis, while the other did not demonstrate late‐gadolinium enhancement.

Cardiac Structural Findings in iMVP and SCD {#jah33692-sec-0016}
-------------------------------------------

Cardiac structural findings are summarized in Table [4](#jah33692-tbl-0004){ref-type="table"}.

###### 

Cardiac Structural Findings Based on Autopsy Reports, Surgical Reports, or Cardiac Investigations

  Cardiac Structural Findings                                         All Cases        iMVP             Non‐iMVP
  ------------------------------------------------------------------- ---------------- ---------------- ---------------
  Mitral valve changes                                                n=88             n=73             n=15
  Redundant leaflet(s)[a](#jah33692-note-0020){ref-type="fn"}         87 (99)          72 (99)          15 (100)
  Annulus circumference, mm[b](#jah33692-note-0021){ref-type="fn"}    n=19             n=15             n=4
  Range                                                               96--160          100--160         96--135
  Median, IQR                                                         125 (100--136)   126 (113--138)   106 (97--120)
  Anterior leaflet length, mm                                         n=15             n=13             n=2
  Range                                                               20--35           20--35           20--28
  Median, IQR                                                         30 (25--30)      30 (25--30)      
  Posterior leaflet length, mm                                        n=16             n=13             n=3
  Range                                                               15--30           15--30           15--30
  Median, IQR                                                         25 (20--30)      25 (20--30)      28
  Chordal changes                                                     n=56             n=45             n=11
  Normal                                                              3 (5)            2 (4)            1 (9)
  Abnormal[c](#jah33692-note-0022){ref-type="fn"}                     37 (66)          28 (62)          9 (82)
  Ruptured                                                            16 (29)          15 (33)          1 (9)
  Left ventricle histology                                            n=40             n=30             n=10
  Normal[d](#jah33692-note-0023){ref-type="fn"}                       20 (50)          18 (60)          2 (20)
  Abnormal[e](#jah33692-note-0024){ref-type="fn"}                     20 (50)          12 (40)          8 (80)
  Other cardiac abnormalities                                         n=50             n=27             n=23
  Left ventricular hypertrophy or cardiomegaly                        14 (28)          0                14 (61)
  Right ventricular fibrosis[f](#jah33692-note-0025){ref-type="fn"}   6 (12)           5 (19)           1 (4)
  Coronary artery disease[g](#jah33692-note-0026){ref-type="fn"}      6 (12)           0                6 (26)
  Other[h](#jah33692-note-0027){ref-type="fn"}                        6 (12)           5 (19)           1 (4)
  Nil                                                                 18 (36)          17 (63)          1 (4)

IQR indicates interquartile range.

Includes descriptive terms myxomatous, ballooned, thickened, nodose, hooding, floppy, voluminous, opaque, and edematous.

Three additional cases reported a dilated annulus without measurement.

Descriptions included elongated, thickened, and/or fused.

Fifteen normal samples were from 1 series (all samples in that series were normal).[11](#jah33692-bib-0011){ref-type="ref"}

Heterogeneous group of descriptors including fibrosis affecting the interventricular septum (3), interstitial fibrosis (5), extensive papillary muscle fibrosis (1), slight papillary muscle fibrosis (2), subendocardial fibrosis affecting the papillary muscles (2), presence of myxomatous material within the papillary muscles (1), multifocal necrosis (3), high‐grade left ventricular hypertrophy changes (1), and degenerated elastic fibers (1).

One case with arrhythmogenic right ventricular cardiomyopathy (nonisolated mitral valve prolapse \[non‐iMVP\]).

Includes left main coronary disease (1), anomalous right coronary artery (2), coronary vasospasm (1), prior inferior infarct (1), and significant diffuse coronary disease in the setting of pseudoxanthoma elasticum (1).

Includes tricuspid valve prolapse (3) and previous endocarditis (2) (isolated mitral valve prolapse cases) and significant conduction system fibrosis (1) (non‐iMVP case).

John Wiley & Sons, Ltd

Autopsy confirmation of MVP was documented in 73 of the 75 SCD cases. In total, 72 of 73 (99%) cases that commented on the MV described redundant leaflets. Median MV annulus circumference was 126 mm based on 15 cases, while another 2 cases reported a dilated annulus. Median anterior and posterior MV lengths were 30 mm and 25 mm, respectively. Leaflet thickness was not reported in cases of iMVP and SCD. Chordae were described in 45 cases and included generalized abnormalities (62%), rupture (33%), and normal appearance (4%).

Histological abnormalities in the left ventricle were described in 12 of 30 cases (40%), with 3 cases describing fibrosis involving the papillary muscles. From 27 cases that described other cardiac structural findings, 17 cases (63%) had no other abnormal findings, 5 cases (19%) had right ventricular fibrosis, 3 cases (11%) had tricuspid valve prolapse, and 2 cases (7%) had evidence of prior endocarditis.

Nonisolated MVP Cases {#jah33692-sec-0017}
---------------------

For cases of non‐iMVP, there were 11 cases with a probable other cause of death or cardiac arrest including anomalous right coronary artery (2), significant left main coronary disease (1), diffuse coronary disease in the setting of pseudoxanthoma elasticum (1), coronary vasospasm (1), previous inferior infarct (1), arrhythmogenic right ventricular cardiomyopathy (1), Brugada syndrome (1), hypertrophic cardiomyopathy (1), dilated cardiomyopathy (1), and postpartum cardiomyopathy (1). There were a further 27 cases with another possible cause of death or cardiac arrest including nonspecific left ventricular hypertrophy or cardiomegaly (12), conduction system fibrosis (2), possible side effect from antiarrhythmic medications (13), and prolonged QTc (3) or a combination of the above. These cases are identified in Table [S1](#jah33692-sup-0001){ref-type="supplementary-material"}.

Predictors of VAs and SCD {#jah33692-sec-0018}
-------------------------

We identified 22 articles that reported a heterogeneous group of clinical, electrical, and imaging predictors for MVP and its association with various clinical outcomes. A summary of all studies is presented in Table [5](#jah33692-tbl-0005){ref-type="table"}, [3](#jah33692-bib-0003){ref-type="ref"}, [4](#jah33692-bib-0004){ref-type="ref"}, [18](#jah33692-bib-0018){ref-type="ref"}, [39](#jah33692-bib-0039){ref-type="ref"}, [40](#jah33692-bib-0040){ref-type="ref"}, [41](#jah33692-bib-0041){ref-type="ref"}, [42](#jah33692-bib-0042){ref-type="ref"}, [43](#jah33692-bib-0043){ref-type="ref"}, [44](#jah33692-bib-0044){ref-type="ref"}, [45](#jah33692-bib-0045){ref-type="ref"}, [46](#jah33692-bib-0046){ref-type="ref"}, [47](#jah33692-bib-0047){ref-type="ref"}, [48](#jah33692-bib-0048){ref-type="ref"}, [49](#jah33692-bib-0049){ref-type="ref"}, [50](#jah33692-bib-0050){ref-type="ref"}, [51](#jah33692-bib-0051){ref-type="ref"}, [52](#jah33692-bib-0052){ref-type="ref"}, [53](#jah33692-bib-0053){ref-type="ref"}, [54](#jah33692-bib-0054){ref-type="ref"}, [55](#jah33692-bib-0055){ref-type="ref"}, [56](#jah33692-bib-0056){ref-type="ref"} and a full list is presented in Table [S2](#jah33692-sup-0001){ref-type="supplementary-material"}.

###### 

Predictors of VAs or SCD

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author           Year   Study population   Predictor/association          Outcome/Endpoint
  ---------------- ------ ------------------ ------------------------------ -----------------------------------------------------------------------------------
  Clinical                                                                  

  Gaffney^39^      1979   MVP                Higher heart rate\             Clinical severity (combination of symptoms and VAs)
                                             Lower cardiac index            

  Puddu^40^        1983   MVP                Plasma catecholamine level     QTc

  Sniezek^41^      1992   MVP                Adrenaline excretion           Complex VAs (Lown grade ≥3)

  Zuppiroli^42^    1994   MVP                Female                         Complex VAs (Lown grade ≥3)[a](#jah33692-note-0029){ref-type="fn"}

  Babuty^43^       1994   MVP                Age (older)                    Complex VAs (Lown grade ≥3)

  Naksuk^44^       2016   MV surgery         Age (younger)                  PVC reduction post‐surgery in BiMVP

  Fulton^45^       2017   MVP                Female                         PVCs from PM

  Electrical                                                                

  Campbell^46^     1976   MVP                Inferolateral T‐wave changes   VT (\>100bpm for ≥3 beats) or VF

  Babuty^43^       1994   MVP                Late potentials                VT (≥3 beats)

  Bobkowski^47^    2002   MVP                Late potentials                VAs (Lown grade ≥1) and VT (\>120bpm for ≥4 beats)

  Akcay^48^        2010   MVP                QTc dispersion                 VT (\>120bpm for ≥3 beats)[a](#jah33692-note-0029){ref-type="fn"}

  Imaging                                                                   

  Shah^49^         1982   MVP                MR                             Complex VAs (Lown grade ≥3)

  Nishimura^18^    1985   MVP                Redundant leaflets             Sudden death[a](#jah33692-note-0029){ref-type="fn"}

  Kligfield^5^     1985   MVP                MR                             VAs (\>1% PVC frequency or exercise induced PVCs/VT or Lown grade ≥4 complex VAs)

  Sanfilippo^50^   1989   MVP                Anterior leaflet thickness\    VAs (≥10 PVCs/hr or VT at ≥100bpm for ≥3 beats)
                                             MR                             

  Zuppiroli^42^    1994   MVP                Anterior leaflet thickness     Complex VAs (Lown grade ≥3)[a](#jah33692-note-0029){ref-type="fn"}

  Babuty^43^       1994   MVP                MR                             Complex VAs (Lown grade ≥3)

  Zouridakis^51^   2001   MVP                MVP degree\                    QT dispersion[a](#jah33692-note-0029){ref-type="fn"}
                                             Anterior leaflet thickness     

  Turker^52^       2010   MVP                Moderate‐severe MR             VAs (Lown grade ≥1)[a](#jah33692-note-0029){ref-type="fn"}

  Carmo^53^        2010   MVP                Mitral annular disjunction     Non‐sustained VT (NS)

  Han^54^          2010   MVP                LGE in PM                      Complex VAs (Lown grade ≥4)

  Akcay^48^        2010   MVP                Anterior leaflet length        VT (\>120 bpm for ≥3 beats)[a](#jah33692-note-0029){ref-type="fn"}

  Sriram^3^        2013   OHCA               BiMVP                          Appropriate ICD therapies at follow‐up

  Basso^4^         2015   MVP                LGE                            Complex VAs (Lown grade ≥4b or VF)

  Nordhues^55^     2016   MVP                BiMVP                          All‐cause mortality

  Bui^56^          2017   MVP                Myocardial T1 time             Complex VAs (Lown grade ≥3)

  Fulton^45^       2017   MVP                BiMVP\                         PVCs from PM
                                             LGE in PM                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

BiMVP indicates bileaflet mitral valve prolapse; bpm, beats per minute; ICD, implantable cardioverter‐defibrillator; LGE, late‐gadolinium enhancement; MR, mitral regurgitation; MV, mitral valve; MVP, mitral valve prolapse; OHCA, out‐of‐hospital cardiac arrest; NS, not specified; PM, papillary muscle; PVCs, premature ventricular complexes; QTc, corrected QT; SCD, sudden cardiac death; VAs, ventricular arrhythmias; VF, ventricular fibrillation; VT, ventricular tachycardia.

Significant result on multivariate analysis; significant univariable predictors are not presented.

John Wiley & Sons, Ltd

Significant multivariate predictors of various outcomes include female sex and anterior mitral leaflet thickness for Lown grade ≥3 complex VAs, QTc dispersion and anterior mitral leaflet length for VT, moderate to severe MR for PVCs and VAs, degree of MVP and anterior mitral leaflet thickness for QT dispersion, and leaflet redundancy for SCD.

Incidence of SCD in MVP {#jah33692-sec-0019}
-----------------------

We identified 3 prospective articles that described SCD events in patients with MVP (Table [6](#jah33692-tbl-0006){ref-type="table"}.[18](#jah33692-bib-0018){ref-type="ref"}, [19](#jah33692-bib-0019){ref-type="ref"}, [20](#jah33692-bib-0020){ref-type="ref"} ^.^

###### 

Prospective Follow‐Up Studies in MVP With SCD Rates

  Study Author                                        Patients, No.                                Mean Age, y   Females, No.   Mean Follow‐Up, y   SCD Events/100 000 Patient‐Y, No.
  --------------------------------------------------- -------------------------------------------- ------------- -------------- ------------------- -----------------------------------
  Nishimura[18](#jah33692-bib-0018){ref-type="ref"}   237[a](#jah33692-note-0031){ref-type="fn"}   44            142            6.2                 408
  Düren[19](#jah33692-bib-0019){ref-type="ref"}       300                                          42            164            6.2                 219
  Zuppiroli[20](#jah33692-bib-0020){ref-type="ref"}   316                                          42            220            8.5                 112

MVP indicates mitral valve prolapse.

A total of 97 patients had redundant leaflets---all cases of sudden cardiac death (SCD) occurred in those with redundant leaflets.

John Wiley & Sons, Ltd

Incidence of SCD ranged from 112 to 408 events per 100 000 person‐years, with an aggregate incidence of 217 events per 100 000 patient‐years (total 13 events in 5985.4 person‐years of follow‐up). One additional study described a pediatric cohort (mean age, 9.9 years) of patients with MVP with no SCD events during 814 person‐years of follow‐up.[57](#jah33692-bib-0057){ref-type="ref"}

Discussion {#jah33692-sec-0020}
==========

This systematic review of all identified cases of cardiac arrest in patients with MVP demonstrates the following key features in patients with iMVP and SCD: 1Clinical characteristicsaMedian age of 30 years (range 6--79 years) and 69% were femalebA total of 47% of cases occurred during physiological or psychological stress2Cardiac electrophysiological findingsaFrequent PVCs or VAs (92% on Holter monitoring)bVF is the primary rhythm (81%) in cardiac arrest and death3Cardiac imaging findingsaPredominant (70%) bileaflet MVPbModerate MR or less in 83%4Histopathological findingsaRedundant leaflets in 99%bAbnormal chordae in 96%5Clinical predictors for SCD in MVPaLacks robust evidence with heterogenous predictors and end pointsbLeaflet redundancy is the only independent predictor of SCD in patients with MVP6Estimated incidence of SCD in MVP is 217 events per 100 000 person‐years

Clinical Characteristics {#jah33692-sec-0021}
------------------------

The median age at time of cardiac arrest or SCD was 30 years, although this was 28 years in females and 39 years in males. The age‐sex distribution graph for the cases demonstrated a peak in female cases between 20 and 30 years consistent with previous data relating to iMVP and SCD.[3](#jah33692-bib-0003){ref-type="ref"}, [42](#jah33692-bib-0042){ref-type="ref"} Cases of MVP‐related cardiac arrest or SCD in males appeared evenly distributed throughout life.

There appeared to be a disproportionately large number of cases (47%) related to situations of stress (physical, emotional, driving, pregnancy, and in‐hospital). The association between increased adrenergic state and complex VAs may provide a plausible explanation as to why autonomic fluctuations may be important in the pathogenesis of iMVP related SCD.[41](#jah33692-bib-0041){ref-type="ref"}

Cardiac Electrical Findings {#jah33692-sec-0022}
---------------------------

From this large collection of MVP cases with cardiac arrest rhythm, VF appears to be primarily responsible for iMVP‐related SCD. Where documented, most were PVC triggered. Only 2 cases described cardiac arrest caused by asystole, with 1 patient having exercise‐induced asystole and 1 patient having a likely vagal reaction.[58](#jah33692-bib-0058){ref-type="ref"}, [59](#jah33692-bib-0059){ref-type="ref"} These findings support a primary arrhythmogenic cause of SCD in patients with iMVP.

Common ECG changes included the presence of inferolateral T‐wave inversion and PVCs on ECG and the presence of PVCs and VAs on Holter monitoring. However, despite the postulation that inferior T‐wave changes on ECG are associated with a potentially high‐risk MVP subtype,[3](#jah33692-bib-0003){ref-type="ref"}, [34](#jah33692-bib-0034){ref-type="ref"} prospective evidence is lacking. Similarly, despite reports of a high incidence of PVCs and VAs on Holter monitoring,[60](#jah33692-bib-0060){ref-type="ref"} these findings have not been prospectively correlated to SCD events in patients with MVP.

Inducible VAs on programmed ventricular stimulation does not appear to predict SCD events in patients with MVP.[61](#jah33692-bib-0061){ref-type="ref"} Two cases in this study reported programmed ventricular stimulation findings before SCD and both cases did not induce VAs.[36](#jah33692-bib-0036){ref-type="ref"}, [62](#jah33692-bib-0062){ref-type="ref"} Additionally, only 1 of 22 cases (5%) had sustained VT during programmed ventricular stimulation, suggesting that arrhythmia initiation is PVC triggered rather than re‐entrant scar related. As such, the role of electrophysiological extrastimuli testing in identifying a potential high‐risk MVP subtype may be limited.

Cardiac Imaging Findings {#jah33692-sec-0023}
------------------------

The presence of bileaflet prolapse has been associated with an increased rate of VAs and cardiac arrest.[3](#jah33692-bib-0003){ref-type="ref"}, [45](#jah33692-bib-0045){ref-type="ref"} This is consistent with our findings where a bileaflet phenotype was present in 70% of cases of SCD or cardiac arrest. The association between bileaflet prolapse, mitral annular disjunction, and VAs indicates that mitral apparatus abnormalities likely play a contributory role in the development of malignant VAs.[63](#jah33692-bib-0063){ref-type="ref"}

Although prior studies suggest that severe MR is correlated with VAs,[5](#jah33692-bib-0005){ref-type="ref"} we found no association between them. Where degree of MR was reported, the majority (83%) of patients experienced cardiac arrest in the setting of nonsevere MR. Whether surgery on the MV may mitigate risk of cardiac arrest is also unclear. Patients who underwent MV surgery had variable results, including 2 cases that experienced recurrent VAs requiring defibrillator therapy post‐MV surgery.[64](#jah33692-bib-0064){ref-type="ref"} The lack of systematic reporting and long‐term follow‐up limits our interpretation.

Other cardiac imaging parameters that may be important include degree of redundancy,[18](#jah33692-bib-0018){ref-type="ref"} mitral annular dilatation,[63](#jah33692-bib-0063){ref-type="ref"} mitral annular disjunction,[63](#jah33692-bib-0063){ref-type="ref"} and anterior mitral leaflet thickness and length.[42](#jah33692-bib-0042){ref-type="ref"}, [48](#jah33692-bib-0048){ref-type="ref"} Unfortunately, few studies documented findings in regard to these parameters. Furthermore, although previous work has suggested that radiological myocardial fibrosis may be a trigger for complex VAs in MVP,[4](#jah33692-bib-0004){ref-type="ref"}, [45](#jah33692-bib-0045){ref-type="ref"} results from cardiac magnetic resonance imaging were only available in 2 studies, limiting interpretation. Studies that prospectively evaluate cardiac imaging parameters with systematic reporting of longitudinal outcomes are required.

Cardiac Structural Findings {#jah33692-sec-0024}
---------------------------

Where reported, 99% of cases described mitral leaflet redundancy, and MV annulus diameter was dilated compared with population data.[65](#jah33692-bib-0065){ref-type="ref"} Anterior and posterior mitral leaflet length were also greater than otherwise expected.[66](#jah33692-bib-0066){ref-type="ref"} Abnormal chordal findings were present in 96% of cases. The combination of morphological valve distortion and chordal abnormalities are consistent with other autopsy studies of patients with MVP[66](#jah33692-bib-0066){ref-type="ref"}, [67](#jah33692-bib-0067){ref-type="ref"} and provide further support that mitral apparatus abnormalities have a contributory role in the development of SCD.

There were 30 cases where cardiac histopathological findings were described. Among these, 12 cases reported abnormal left ventricular histological changes, including 3 cases that specifically described histological abnormalities involving the papillary muscles. Left ventricular fibrosis, especially near the papillary muscles, is described in autopsy patients with MVP and may provide a substrate for the development of VAs.[4](#jah33692-bib-0004){ref-type="ref"}, [68](#jah33692-bib-0068){ref-type="ref"} These findings suggest that both diffuse and focal changes within the left ventricle occur in patients with MVP, which may act as a substrate for the development of VAs.

Findings in Non‐iMVP {#jah33692-sec-0025}
--------------------

As described, there was a subset of patients with SCD and MVP but also other cardiac abnormalities.

SCD is likely attributable to significant coronary artery disease, dilated or hypertrophic cardiomyopathy, Brugada syndrome, and arrhythmogenic right ventricular cardiomyopathy in cases with these coexistent conditions.

Other coexistent findings are more contentious. Anatomical findings such as mild left ventricular hypertrophy or cardiomegaly at autopsy have been described in relation to MVP[69](#jah33692-bib-0069){ref-type="ref"} and could indicate that pathological changes of the ventricle in otherwise "iMVP" is a contributor to SCD events. Additionally, 13 patients were taking antiarrhythmic medications. It is prudent to consider that while these medications in themselves may have proarrhythmic side effects, these medications were likely administered to treat preexisting VAs in the cases. Finally, findings of prolonged QTc may also reflect underlying repolarization abnormalities in patients with MVP, which has also been previously described.[48](#jah33692-bib-0048){ref-type="ref"}, [51](#jah33692-bib-0051){ref-type="ref"} ^.^

Challenges in Predicting SCD in Patients With Isolated MVP {#jah33692-sec-0026}
----------------------------------------------------------

Studies investigating premortem predictors of SCD in MVP are limited. One prospective study demonstrated that leaflet redundancy was an independent predictor of SCD.[18](#jah33692-bib-0018){ref-type="ref"} Some controversy surrounds the risk of bileaflet MVP with 1 study suggesting that it was associated with appropriate implantable cardioverter‐defibrillator therapies,[3](#jah33692-bib-0003){ref-type="ref"} while another suggested that bileaflet MVP was associated with lower all‐cause mortality based on registry data.[55](#jah33692-bib-0055){ref-type="ref"}

Premortem predictors of VAs are difficult to validate in the current collection of cases. Some predictors such as leaflet redundancy, bileaflet MVP, and inferolateral T‐wave inversion on ECG were only available in approximately half of the case reports, while degree of MR was available for about one quarter of cases. Other potential predictors such as catecholamine levels, late potentials, QT dispersion, anterior mitral leaflet thickness and length, mitral annular disjunction, presence of late‐gadolinium enhancement, and myocardial T1 time were either scarcely reported or not reported.

In addition, many studies have used VAs or repolarization abnormalities as surrogate end points for SCD because of the relatively low event rates of SCD. These end points, which include nonsustained ventricular tachycardia, Lown grade VAs of varying degrees, PVC frequency, exercise‐induced PVCs, presence of papillary muscle PVCs, PVC reduction post‐MV surgery, corrected QT interval, or QT dispersion, are yet to be validated as predictors of SCD in the MVP population.

The heterogeneous nature of these predictors and end points limits comparisons between studies. As such, despite the numerous cases reporting SCD or cardiac arrest in MVP, there is limited evidence that such outcomes can be reliably predicted.

Incidence of SCD in MVP {#jah33692-sec-0027}
-----------------------

Our findings suggest that the overall incidence of SCD in MVP was 217 events per 100 000 person‐years based on 3 prospective studies, although the presence of leaflet redundancy may signal a higher risk cohort. Extrapolation of data from Nishimura et al[18](#jah33692-bib-0018){ref-type="ref"} suggests an approximate event rate of 998 per 100 000 person‐years in patients with evidence of leaflet redundancy.

Comparisons to population data are inherently limited (Figure [5](#jah33692-fig-0005){ref-type="fig"}). More recent population‐based studies indicate that the incidence of SCD in the general population has decreased from 94 to 97 events per 100 000 person‐years in the 1990s to 42 to 53 events per 100 000 person‐years in the 2000s,[70](#jah33692-bib-0070){ref-type="ref"}, [71](#jah33692-bib-0071){ref-type="ref"}, [72](#jah33692-bib-0072){ref-type="ref"}, [73](#jah33692-bib-0073){ref-type="ref"}, [74](#jah33692-bib-0074){ref-type="ref"} although advances in resuscitation methods may account for some of this difference. Framingham data (involving an older and more male‐predominant cohort) suggest that the SCD risk in the general population was ≈130 events per 100 000 person‐years during the 1980s,[71](#jah33692-bib-0071){ref-type="ref"} around the time of the 3 prospective studies.

![Sudden cardiac death (SCD) incidence in mitral valve prolapse (MVP) versus population studies.](JAH3-7-e010584-g005){#jah33692-fig-0005}

Limitations {#jah33692-sec-0028}
-----------

This is the largest systematic review of published cases of MVP and SCD or cardiac arrest. We sought to provide comprehensive insight into clinical, electrical, imaging, and histopathological characteristics. Our results highlight some significant challenges when attempting to characterize a potential high‐risk MVP subtype.

The cases that describe MVP and SCD or cardiac arrest span over 50 years. Our understanding of MVP has evolved significantly over that time. Changes in clinical medicine affect the reproducibility of various diagnostic tests, especially echocardiography for the diagnosis of MVP. Information regarding clinical, electrical, imaging, and histopathological characteristics were inconsistently described and are subject to reporting and publication bias. Notably, a lack of systematic reporting regarding these characteristics likely affected their prevalence within this collection of cases.

Further work is required to validate many of the current reported predictors. The disconnect between premortem predictors and available information from SCD cases limits our ability to determine whether these factors may be important in the development of SCD and cardiac arrest.

Finally, despite all the published literature hypothesizing that SCD in MVP is caused by malignant VAs, there are only 6 cases describing autopsy‐proven iMVP with documentation of cardiac arrest rhythm. Further correlations of cardiac arrest rhythm with pathological description is warranted.

Conclusions {#jah33692-sec-0029}
===========

Our systematic review indicates that iMVP and SCD predominantly affects young females. The MV leaflets are frequently redundant with bileaflet prolapse, associated chordal abnormalities, and nonsevere MR. Electrophysiological changes include frequent PVCs on Holter monitoring and VF as the predominant cardiac arrest rhythm. Current predictors for SCD events in iMVP lack robust evidence. To better understand the complex relationship between MVP and SCD, standardized reporting of clinical, electrophysiological, echocardiographic, and other cardiac imaging variables with documentation of long‐term outcomes is required.
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